OPNT SEC Filings - Opiant Pharmaceuticals Inc- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1385508

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Opiant Pharmaceuticals Inc

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

March 13, 2023	15-12G	As filed with the Securities and Exchange Commission on March 13, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHA 15-12G As filed with the Securities and Exchange Commission on March 13, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 6, 2023	S-8 POS	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No.
March 6, 2023	S-8 POS	As filed with the Securities and Exchange Commission on March 6, 2023 S-8 POS 1 projectrainbow-sx8postxeff.htm S-8 POS As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. 333-263636 Registration No. 333-254082 Registration No. 333-237050 Registration No. 333-230450 Registration No. 333-224239 Registration No. 333-221759 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-
March 6, 2023	POS AM	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration Statement File No.
March 6, 2023	S-8 POS	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No.
March 6, 2023	POS AM	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration Statement File No.
March 6, 2023	S-8 POS	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No.
March 6, 2023	S-8 POS	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No.
March 6, 2023	S-8 POS	As filed with the Securities and Exchange Commission on March 6, 2023 S-8 POS 1 projectrainbow-sx8postxeff.htm S-8 POS As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. 333-263636 Registration No. 333-254082 Registration No. 333-237050 Registration No. 333-230450 Registration No. 333-224239 Registration No. 333-221759 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-
March 6, 2023	POS AM	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration Statement File No.
March 2, 2023	EX-3.1	Amended and Restated Certificate of Incorporation of Opiant Pharmaceuticals, Inc. Exhibit 3.1 Execution Version AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OPIANT PHARMACEUTICALS, INC. ARTICLE 1 NAME The name of the corporation is Opiant Pharmaceuticals, Inc. (the “Corporation”). ARTICLE II REGISTERED OFFICE AND REGISTERED AGENT The address of the Corporation’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, City of Wi
March 2, 2023	EX-3.2	Second Amended and Restated Bylaws of Opiant Pharmaceuticals, Inc. Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF OPIANT PHARMACEUTICALS, INC. a Delaware corporation (hereinafter referred to as the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office and the registered agent of the Corporation are as set forth in the Certificate of Incorporation. Section 2. Other Offices. The Corporation may also have offices at such other place
March 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 OPIANT PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 OPIANT PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
February 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 OPIANT PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
February 22, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Def
February 16, 2023	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
February 15, 2023	SC 13G/A	OPNT / Opiant Pharmaceuticals Inc / Western Standard LLC - SC 13G/A Passive Investment SC 13G/A 1 d449015dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class Securities) 683750103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) C
February 15, 2023	EX-99.A	Joint Filing Agreement Pursuant to Rule 13d-1 EX-99.A 2 d449015dex99a.htm EX-99.A Page 9 of 9 Pages Exhibit A Joint Filing Agreement Pursuant to Rule 13d-1 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating
February 7, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Def
February 7, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
February 7, 2023	EX-99.2	Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC Exhibit 99.2 Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC •CFIUS clearance represents the final required regulatory approval to complete the proposed merger •Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 •Indivior and Opiant continue to anticipate
February 7, 2023	EX-99.1	Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC Exhibit 99.1 Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC SANTA MONICA, Calif., February 6, 2023 – Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agre
February 6, 2023	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 OPIANT PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commi
January 4, 2023	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFM14A 1 projectrainbow-definitivep.htm DEFM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, f
December 21, 2022	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
December 21, 2022	EX-FILING FEES	Calculation of Filing Fee Tables SCHEDULE 14A (Form Type) OPIANT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 – Transaction Value Exhibit 107 Calculation of Filing Fee Tables SCHEDULE 14A (Form Type) OPIANT PHARMACEUTICALS, INC.
December 20, 2022	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
December 7, 2022	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
November 28, 2022	SC 13G	OPNT / Opiant Pharmaceuticals Inc / Western Standard LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class Securities) 683750103 (CUSIP Number) November 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
November 15, 2022	EX-10.3	Termination Agreement, dated November 13, 2022, by and among Opiant Pharmaceuticals, Inc. and SWK Funding LLC Exhibit 10.3 TERMINATION AGREEMENT This Termination Agreement (this ?Agreement?), is made as of 13th day of November, 2022 (?Effective Date?), by and among Opiant Pharmaceuticals, Inc., a Delaware corporation (the ?Seller?) and SWK Funding LLC (the ?Purchaser?). The Seller and the Purchaser are sometimes referred to herein individually as a ?Party? and collectively as the ?Parties.? WHEREAS, the S
November 15, 2022	EX-10.2	First Amendment to Note Purchase and Security Agreement, dated November 13, 2022, by and among Opiant Pharmaceuticals, Inc. and the parties named therein Exhibit 10.2 FIRST AMENDMENT TO NOTE PURCHASE AND SECURITY AGREEMENT This FIRST AMENDMENT TO NOTE PURCHASE AND SECURITY AGREEMENT, dated as of November 13, 2022 (this ?First Amendment?), is entered into by and among Opiant Pharmaceuticals, Inc., a Delaware corporation (?Parent?) and Opiant Pharmaceuticals UK Ltd., a corporation incorporated in the United Kingdom, (together with Parent, collectivel
November 15, 2022	EX-10.4	Form of Voting Agreement, dated November 13, 2022, by and among Indivior Exhibit 10.4 VOTING AGREEMENT THIS VOTING AGREEMENT, dated as of November 13, 2022 (this ?Agreement?), is entered into by and between Indivior Inc., a Delaware corporation (?Parent?), and each of the individuals or entities listed on the signature pages hereto (each, a ?Stockholder? and, together, the ?Stockholders?). RECITALS A. Concurrently with the execution and delivery of this Agreement, Pare
November 15, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant ? Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Def
November 15, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Defin
November 15, 2022	EX-10.1	Amended and Restated License and Settlement Agreement, dated November 13, 2022, by and among Opiant Pharmaceuticals, Inc. and Emergent Operations Ireland Limited Exhibit 10.1 AMENDED AND RESTATED LICENSE AND SETTLEMENT AGREEMENT between OPIANT PHARMACEUTICALS INC. and EMERGENT OPERATIONS IRELAND LIMITED Dated as of November 13, 2022 1 AMENDED AND RESTATED LICENSE AND SETTLEMENT AGREEMENT This Amended and Restated License and Settlement Agreement (the ?Agreement?) is made and entered into effective as of November 13, 2022 (the ?Effective Date?), by and betw
November 15, 2022	EX-2.1	Agreement and Plan of Merger, dated as of November 13, 2022, by and among Opiant Pharmaceuticals, Inc., Indivior Inc., and Olive Acquisition Subsidiary, Inc. (Form of CVR Agreement included as Exhibit B thereto) Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among INDIVIOR INC., OLIVE ACQUISITION SUBSIDIARY, INC. and OPIANT PHARMACEUTICALS, INC. dated as of November 13, 2022 TABLE OF CONTENTS Page ARTICLE I. THE MERGER ......................................................................................................... 1 The Merger .....................................................................
November 15, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIA
November 14, 2022	EX-99.1	Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results Exhibit 99.1 Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results SANTA MONICA, Calif., Nov 14, 2022 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and nine months ended September 30, 2022. Recent highlights include: Financ
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2022 OPIANT PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT PH
August 11, 2022	EX-99.1	Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update SANTA MONICA, Calif., Aug 11, 2022 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30,
August 11, 2022	EX-10.1	Capacity Investment Agreement between Aptar Group Inc. and Opiant Pharmaceuticals, Inc. dated June 8, 2022. CAPACITY INVESTMENT AGREEMENT between APTAR FRANCE SAS APTARGROUP, INC. and OPIANT PHARMACEUTICALS, INC. *Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed* THIS capacity investment agreement (the ?Agreement?) is dated 7th of June 2022 (the "Effective Date") and made
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commi
June 17, 2022	SC 13D/A	OPNT / Opiant Pharmaceuticals Inc / Sinclair Michael - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) Dr. Michael Sinclair c/o Opiant Pharmaceuticals, Inc. 233 Wilshire Blvd., Suite 400 Santa Monica, CA 90401 (310)
June 17, 2022	SC 13D/A	OPNT / Opiant Pharmaceuticals Inc / Crystal Roger - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) Dr. Roger Crystal c/o Opiant Pharmaceuticals, Inc. 233 Wilshire Blvd., Suite 400 Santa Monica, CA 90401 (310) 59
June 14, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
June 8, 2022	EX-99.1	Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene Exhibit 99.1 Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene ?Long-term agreement includes a ?2 million (approximately $2.1 million) investment by Opiant to expand Aptar?s production in support of OPNT003 SANTA MONICA, Calif., June 8, 2022 - Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today anno
June 8, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissi
May 23, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the ? Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissi
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT P
May 10, 2022	EX-99.1	Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update SANTA MONICA, Calif., May 10, 2022 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporat
April 27, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
April 27, 2022	EX-99.1	Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone Exhibit 99.1 Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone ?Study compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioid ?OPNT003 met the primary endpoint of non-inferiority, which was desig
April 18, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive P
March 17, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLE Form S-8 (Form Type) Opiant Pharmaceuticals, Inc.
March 17, 2022	S-8	As filed with the Securities and Exchange Commission on March 17, 2022 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.
March 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
March 15, 2022	EX-99.1	Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update SANTA MONICA, Calif., March 15, 2022 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31
March 15, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38193 OPIANT PHARMACEUTICALS, INC. (Exact name of Registrant as s
March 15, 2022	EX-4.2	Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. EX-4.2 2 exhibit421.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Opiant Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock, par value $0.001 per share. As used in this summary, the terms “Opiant
January 27, 2022	SC 13G/A	OPNT / Opiant Pharmaceuticals Inc / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) OPIANT PHARMACEUTICALS INC (Name of Issuer) COM (Title of Class of Securities) 683750103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
January 7, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commi
December 13, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
December 13, 2021	EX-10.1	2021 Inducement Equity Incentive Plan, as amended on December 9, 2021 Exhibit 10.1 OPIANT PHARMACEUTICALS, INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN As Amended on December 9, 2021 1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The
November 12, 2021	EX-99.1	Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update SANTA MONICA, Calif., November 11, 2021 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and nine months ended September 30, 2021, and p
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIA
November 8, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
November 8, 2021	EX-99.1	Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose Exhibit 99.1 Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose ?Fast Track Designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge1 ?This designation enables early and frequent communication with the FDA, in addition to the potential for a rolli
August 19, 2021	CORRESP	OPIANT PHARMACEUTICALS, INC. 233 Wilshire Blvd., Suite 280 Santa Monica, California 90401 OPIANT PHARMACEUTICALS, INC. 233 Wilshire Blvd., Suite 280 Santa Monica, California 90401 August 19, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4561 Attn: Dillon Hagius Re: Opiant Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-258813 Filed August 13, 2021 Dear Mr. Hagius: Opiant Phar
August 13, 2021	EX-1.2	by and between Opiant Pharmaceuticals, Inc. and Cantor & Fitzgerald & Co Exhibit 1.2 OPIANT PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement August 13, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Opiant Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follow
August 13, 2021	S-3	As filed with the Securities and Exchange Commission on August 13, 2021 S-3 1 opnt2021s3.htm S-3 As filed with the Securities and Exchange Commission on August 13, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4744124 (State or other jurisdiction of incorporat
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT PH
August 5, 2021	EX-32.10	Certification of the Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc. (the “Company”) for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dr. Roger Crystal, as Chief Executive Office
August 5, 2021	EX-32.20	Certification of the Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. EXHIBIT 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc. (the ?Company?) for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), David O'Toole, as Chief Financial Officer of
August 5, 2021	EX-31.20	Certification of the Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES–OXLEY ACT OF 2002 I, David O'Toole, Chief Financial Officer of Opiant Pharmaceuticals, Inc., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any un
August 5, 2021	EX-31.10	Certification of the Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES–OXLEY ACT OF 2002 I, Dr. Roger Crystal, Chief Executive Officer of Opiant Pharmaceuticals, Inc., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain an
August 5, 2021	EX-99.1	Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update SANTA MONICA, Calif., August 5, 2021 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and six months ended June 30, 2021, and provided
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
July 12, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissi
July 12, 2021	EX-10.1	2021 Inducement Equity Incentive Plan and Form of Option Agreement Exhibit 10.1 OPIANT PHARMACEUTICALS, INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nons
July 12, 2021	EX-99.1	Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer Exhibit 99.1 Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer ?Mr. Ruth led the highly successful launch and commercialization of the first FDA- approved nasal naloxone spray to treat opioid overdose ?He joins Opiant at a time when the Company is developing and moving towards potential commercialization of OPNT003, nasal nalmefene, a novel investigational tr
July 6, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissi
July 6, 2021	EX-99.1	Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose Exhibit 99.1 Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose ?Data demonstrate rapid absorption and higher plasma concentrations versus an intramuscular injection (p<0.0001) ?Results confirm findings of initial pilot PK study SANTA MONICA, Calif., July 6, 2021 -
June 15, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
May 19, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the ? Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
May 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissi
May 11, 2021	EX-99.1	Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update SANTA MONICA, Calif., May 11, 2021 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2021, and provided a corporate update.
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT P
April 19, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive P
April 13, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
April 8, 2021	PREM14A	- PREM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive P
March 22, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
March 22, 2021	EX-10.1	Director Agreement, effective March 18, 2021, by and between Opiant Pharmaceuticals, Inc. and Dr. Lorianne Masuoka Exhibit 10.1 OPIANT PHARMACEUTICALS, INC. DIRECTOR AGREEMENT This DIRECTOR AGREEMENT (this ?Agreement?) by and between Dr. Lorianne Masuoka (?Director?) and Opiant Pharmaceuticals, Inc. (?Company?), with its corporate headquarters at 233 Wilshire Blvd., Suite 280, Santa Monica, CA 90401, is dated and effective as of March 18, 2021 (the ?Appointment Date?). W I T N E S S E T H: WHEREAS, Company wis
March 22, 2021	EX-99.1	Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D. Exhibit 99.1 Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D. SANTA MONICA, Calif., March 22, 2021 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Lorianne Masuoka, MD, to
March 11, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
March 10, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 10, 2021 Registration No.
March 4, 2021	EX-99.1	Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update SANTA MONICA, Calif., March 4, 2021 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2
March 4, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38193 OPIANT PHARMACEUTICALS, INC. (Exact name of Registrant as s
March 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
March 4, 2021	EX-4.2	Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Opiant Pharmaceuticals, Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock, par value $0.001 per share. As used in this summary, the terms ?Opiant,? ?the Company,? ?we,? ?our? a
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 683750103 (CUSIP Num
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
February 11, 2021	EX-1	Joint Acquisition Statement Pursuant to Section 240.13d-1(k) EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Altium Capital Management, LP SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersig
February 11, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 11, 2021	SC 13G	SCHEDULE 13G SIGNATURE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) OPIANT PHARMACEUTICALS INC (Name of Issuer) COM (Title of Class of Securities) 683750103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul
January 28, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
January 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
January 21, 2021	CORRESP	- January 21, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: David Gessert Re: Opiant Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-252012 Acceleration Request Requested Date: January 25, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the
January 11, 2021	S-3	- S-3 As filed with the Securities and Exchange Commission on January 11, 2021 Registration No.
December 14, 2020	EX-99.1	Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program Exhibit 99.1 Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program SANTA MONICA, Calif., December 14, 2020 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office
December 14, 2020	EX-10.1	Amendment of Solicitation/Modification of Contract bardamodification December 11, 2020 Exhibit 10.1 ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT NAME OF OFFEROR OR CONTRACTOR 2 8 CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED PAGE OF OPIANT PHARMACEUTICALS, INC 1530943 (A) (B) (C) (D) (E) (F) HHSO100201800029C/P00005 $6,471,230.00. The contract overall value is increased by $3,500,000.00 from $4,590,280.00 to $8,090,280
December 14, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
December 10, 2020	EX-4.1	Registration Rights Agreement, dated December 10, 2020, by and among the Company and the parties named therein (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed December 10, 2020). Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of December 10, 2020 by and among Opiant Pharmaceuticals, Inc., a corporation incorporated in the State of Delaware (the ?Company?), and the ?Lenders? named in that certain Note Purchase and Security Agreement by and among the Company and the Lenders, dated the date hereof (t
December 10, 2020	EX-99.1	Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing Exhibit 99.1 Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing SANTA MONICA, Calif., December 10, 2020 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (?Agreement?) wit
December 10, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
December 10, 2020	EX-10.1	Note Purchase and Security Agreement, dated December 10, 2020, by and among the Company and the parties named therein (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 10, 2020). Exhibit 10.1 NOTE PURCHASE AND SECURITY AGREEMENT THIS NOTE PURCHASE AND SECURITY AGREEMENT is made and dated as of December 10, 2020 and is entered into by and between Opiant Pharmaceuticals, Inc., a corporation incorporated in the State of Delaware (?Parent?), Opiant Pharmaceuticals UK Ltd. a corporation incorporated in the United Kingdom and each of Parent?s other Subsidiaries from time to time
November 18, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
November 12, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIA
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
November 12, 2020	EX-10.1	Press Release of Opiant Press Release of Opiant Pharmaceuticals, Inc., dated November 12, 2020, Inc., dated November 12, 2020 Exhibit 10.1 Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update SANTA MONICA, Calif., Nov 12, 2020 - Opiant Pharmaceuticals, Inc. (?Opiant?) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended September 30, 2020, and provided a corporate upd
October 29, 2020	EX-10.1	Master Services Agreement dated October 26, 2020 between the Company and AptarGroup, Inc. Exhibit 10.1 APTAR AND OPIANT CONFIDENTIAL MASTER SERVICES AGREEMENT This MASTER SERVICES AGREEMENT (“Agreement”) is made this 21st day of October, 2020 (“Effective Date”) by and between AptarGroup, Inc., a Delaware corporation, by and on behalf of its Affiliates, having its principal place of business at 265 Exchange Drive, Suite 100, Crystal Lake, Illinois 60014 (“Aptar”), and Opiant Pharmaceuti
October 29, 2020	EX-99.1	Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment Exhibit 99.1 Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment •Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device •Reinforces Opiant’s continued commitment to innovative overdose treatment options as America’s opioid epidemic worsens •OPNT003 nasal nalmefene remains on trac
October 29, 2020	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
August 6, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT PH
August 6, 2020	EX-99.1	Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update SANTA MONICA, Calif., Aug 6, 2020 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended June 30, 2020, and provided a corporate update.
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
July 28, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
July 28, 2020	EX-10.1	Master Services Agreement dated July 1, 2020 and Project Scope Agreement dated July 22, 2020 between the Company and Summit Biosciences, Inc. Exhibit 10.1 MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement” or “MSA”) is made effective as of July 1, 2020 (the “Effective Date”) by and between OPIANT PHARMACEUTICALS, INC., with principal executive offices at 233 Wilshire Blvd., Suite 280, Santa Monica, CA 90401 (“Client”) and SUMMIT BIOSCIENCES INC., with principal executive offices at Coldstream Research Campus, 151
June 16, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
June 8, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissi
June 8, 2020	EX-99.1	Opiant Pharmaceuticals Statement on U.S. District Court Decision Exhibit 99.1 Opiant Pharmaceuticals Statement on U.S. District Court Decision SANTA MONICA, Calif., June 5, 2020 – Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals Industries Ltd. Opiant’s commercial partner Emerge
May 21, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant þ Filed by a Party other than the ¨ Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
May 12, 2020	EX-99.1	Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update SANTA MONICA, Calif., May 12, 2020 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2020, and provided a corporate update.
May 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissi
May 12, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT P
April 29, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive P
March 25, 2020	EX-99.1	A Letter to Opiant Stockholders Regarding the Coronavirus Pandemic Exhibit 99.1 A Letter to Opiant Stockholders Regarding the Coronavirus Pandemic March 25, 2020 Dear Stockholders: I felt it was important, as we face the Coronavirus pandemic, to give you an update on where we stand at Opiant. While the world works to combat this virus and manage the spread, possibly for an extended period of time, there are challenges common to many companies around the globe. Ou
March 25, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
March 20, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
March 10, 2020	S-8	OPNT / Opiant Pharmaceuticals, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on March 10, 2020 Registration No.
March 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
March 4, 2020	EX-4.2	Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Opiant Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock, par value $0.001 per share. As used in this summary, the terms “Opiant,” “the Company,” “we,” “our” a
March 4, 2020	EX-99.1	Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update SANTA MONICA, Calif., March 4, 2020 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2
March 4, 2020	10-K	OPNT / Opiant Pharmaceuticals, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38193 OPIANT PHARMACEUTICALS, INC. (Exact name of Registrant as s
February 18, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
February 14, 2020	SC 13G/A	OPNT / Opiant Pharmaceuticals, Inc. / Radoff Bradley Louis - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 683750103 (CUSIP Num
February 14, 2020	SC 13G/A	OPNT / Opiant Pharmaceuticals, Inc. / Altium Capital Management Lp - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 13, 2020	SC 13G/A	OPNT / Opiant Pharmaceuticals, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 683750103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 6, 2020	SC 13D/A	OPNT / Opiant Pharmaceuticals, Inc. / OPIANT PHARMACEUTICALS, INC. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) Dr. Roger Crystal c/o Opiant Pharmaceuticals, Inc. 233 Wilshire Blvd., Suite 280 Santa Monica, CA 90401 (310) 59
February 6, 2020	SC 13D/A	OPNT / Opiant Pharmaceuticals, Inc. / OPIANT PHARMACEUTICALS, INC. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) Dr. Michael Sinclair c/o Opiant Pharmaceuticals, Inc. 233 Wilshire Blvd., Suite 280 Santa Monica, CA 90401 (310)
January 17, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
January 9, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commi
January 8, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commi
November 14, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
November 14, 2019	EX-1.1	Open Market Sale AgreementSM, dated November 14, 2019, by and between Opiant Pharmaceuticals, Inc. and Jefferies LLC. Exhibit 1.1 Execution Version OPEN MARKET SALE AGREEMENTSM November 14, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Opiant Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares
November 14, 2019	424B5	OPIANT PHARMACEUTICALS, INC. Up to $20,000,000 Common Stock PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To prospectus dated November 7, 2017) Registration No.
November 12, 2019	EX-99.1	Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update SANTA MONICA, Calif., Nov. 12, 2019 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the third quarter and nine months ended September 30, 2019, and
November 12, 2019	10-Q	OPNT / Opiant Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIA
November 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
August 8, 2019	EX-99.1	Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update SANTA MONICA, Calif, August 8, 2019 – Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the second quarter and six months ended June 30, 2019 and provided
August 8, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
August 8, 2019	EX-31.10	Certification of the Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES–OXLEY ACT OF 2002 I, Dr. Roger Crystal, Chief Executive Officer of Opiant Pharmaceuticals, Inc., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain an
August 8, 2019	EX-32.10	Certification of the Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dr. Roger Crystal, as Chief Executive O
August 8, 2019	EX-31.20	Certification of the Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES–OXLEY ACT OF 2002 I, David O'Toole, Chief Financial Officer of Opiant Pharmaceuticals, Inc., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any un
August 8, 2019	10-Q	OPNT / Opiant Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT PH
August 8, 2019	EX-32.20	Certification of the Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. EXHIBIT 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David O'Toole, as Chief Financial Offic
July 11, 2019	EX-3.1	Amended and Restated Bylaws of Opiant Pharmaceuticals, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF OPIANT PHARMACEUTICALS, INC. ARTICLE I STOCKHOLDERS 1.1 Place of Meetings. All meetings of stockholders shall be held at such place (if any) within or without the State of Delaware as may be determined from time to time by the Board of Directors or, if not determined by the Board of Directors, by the Chairman of the Board, the Lead Independent Director, t
July 11, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
July 8, 2019	SC 13G	OPNT / Opiant Pharmaceuticals, Inc. / Radoff Bradley Louis Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 683750103 (CUSIP Numb
July 8, 2019	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated July 8, 2019 with respect to the Common Stock, $0.001 par value per share, of Opiant Pharmaceuticals, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1
June 13, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
June 5, 2019	SC 13G	OPNT / Opiant Pharmaceuticals, Inc. / Altium Capital Management Lp - ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 683750103 (CUSIP Number) May 30, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
May 9, 2019	10-Q	OPNT / Opiant Pharmaceuticals, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT P
May 9, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissio
May 9, 2019	EX-99.1	Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update SANTA MONICA, Calif, May 9, 2019 – Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the three months ended March 31, 2019, and provided a corporate update.
April 19, 2019	DEFA14A	OPNT / Opiant Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant þ Filed by a Party other than the ¨ Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
April 18, 2019	DEF 14A	OPNT / Opiant Pharmaceuticals, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive P
April 9, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
March 22, 2019	S-8	OPNT / Opiant Pharmaceuticals, Inc. S-8 As filed with the Securities and Exchange Commission on March 22, 2019 Registration No.
March 21, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
March 21, 2019	EX-99.1	Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update Addiction and Drug Overdose Pipeline Supported by Strong Cash Position; Expected to be in Range of $17M-$20M at End of 2019 EX-99.1 2 opnt4qfy18financialresult.htm EXHIBIT 99.1 Exhibit 99.1 Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update Addiction and Drug Overdose Pipeline Supported by Strong Cash Position; Expected to be in Range of $17M-$20M at End of 2019 SANTA MONICA, Calif, March 21, 2019 – Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT
March 21, 2019	10-K	OPNT / Opiant Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38193 OPIANT PHARMACEUTICALS, INC. (Exact name of Registrant as s
March 21, 2019	EX-10.87	Amendment No. 2 to License Agreement, dated March 18, 2019, by and between Registrant and Adapt Pharma Operations Limited. Exhibit 10.87 AMENDMENT NO. 2 TO LICENSE AGREEMENT This Amendment No. 2 to License Agreement (this “Amendment”) is made as of March 18, 2019, by and between Opiant Pharmaceuticals Inc. (formerly known as Lightlake Therapeutics Inc.), a Delaware corporation (“Opiant”), and Adapt Pharma Operations Limited, an Irish limited company (“Adapt”). Opiant and Adapt are sometimes referred to herein individu
March 21, 2019	EX-32.11	Certification of the Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 10-K of Opiant Pharmaceuticals, Inc. (the “Company") for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Dr. Roger Crystal, as Chief Executive Officer
March 21, 2019	EX-31.11	Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 31.1 CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Roger Crystal, Chief Executive Officer of Opiant Pharmaceuticals, Inc., certify that: 1. I have reviewed this Annual Report on Form 10-K of Opiant Pharmaceuticals, Inc.; 2. Based on my knowledge, this Annual Report does not
March 21, 2019	EX-31.21	Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 31.2 CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David O'Toole, Chief Financial Officer of Opiant Pharmaceuticals, Inc., certify that: 1. I have reviewed this Annual Report on Form 10-K of Opiant Pharmaceuticals, Inc.; 2. Based on my knowledge, this Annual Report does not con
March 21, 2019	EX-32.21	Certification of the Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. EXHIBIT 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 10-K of Opiant Pharmaceuticals, Inc. (the “Company") for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David O'Toole as Chief Financial Officer of t
February 21, 2019	EX-99.1	Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa -Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus rem Exhibit 99.1 Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa -Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus remains on advancing lead product candidate, OPNT003, for treatment of opioid overdose, and other promising addiction and drug overdose-rela
February 21, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
February 13, 2019	SC 13G/A	OPNT / Opiant Pharmaceuticals, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 683750103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 17, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
January 4, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2019 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commi
December 28, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
December 28, 2018	EX-10.1	License Agreement between the Registrant and Sanofi dated December 21, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 28, 2018). Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION LICENSE AGREEMENT between SANOFI and OPIANT PHARMACEUTICALS, INC. Dated as of December 21, 2018 * Certain confidential information contained in this document, marked [***], is filed separately with the Securities and Exch
December 28, 2018	EX-99.1	Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi Opiant Intends to Initiate Development Efforts in 2019 Exhibit 99.1 Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi Opiant Intends to Initiate Development Efforts in 2019 SANTA MONICA, Calif., December 26, 2018 – Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has entered i
December 4, 2018	8-K/A	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of
December 4, 2018	EX-10.86	Contract between the Registrant and Biomedical Advanced Research and Development Authority dated September 19, 2018 (incorporated by reference to Exhibit 10.86 of the Company’s Current Report on Form 8-K/A filed December 4, 2018). EXHIBIT 10.86 * Certain confidential information contained in this document, marked [**], is filed separately with the Securities and Exchange Commission. EXHIBIT 10.86 Certain confidential information contained in this document, marked [***], is filed separately with the Securities and Exchange Commission. EXHIBIT 10.86 CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAV
November 7, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
November 7, 2018	EX-99.1	Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update SANTA MONICA, Calif, November 7, 2018 – Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today reported financial results for the quarter and nine months ended September
November 7, 2018	10-Q	OPNT / Opiant Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIA
November 2, 2018	424B3	OPIANT PHARMACEUTICALS, INC. 166,738 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-220976 PROSPECTUS SUPPLEMENT (To the Prospectus dated November 7, 2017) OPIANT PHARMACEUTICALS, INC. 166,738 Shares of Common Stock This prospectus relates to 166,738 shares of our common stock which may be sold from time to time by certain of our stockholders set forth in the “Selling Stockholders” section of this prospectus. The shares offere
November 2, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
October 29, 2018	EX-10.1	Director Agreement, effective October 29, 2018, by and between Opiant Pharmaceuticals, Inc. and Craig A. Collard. OPIANT PHARMACEUTICALS, INC. DIRECTOR AGREEMENT This DIRECTOR AGREEMENT (this “Agreement”) by and between Craig A. Collard (“Director”) and Opiant Pharmaceuticals, Inc. (“Company”), with its corporate headquarters at 201 Santa Monica Blvd., 5th Floor, Santa Monica, CA 90401, is dated and effective as of October 29, 2018 (the “Appointment Date”). W I T N E S S E T H: WHEREAS, Company wishes to reta
October 29, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Comm
October 9, 2018	EX-1	Letter agreement, dated as of October 4, 2018, between Kevin Pollack and Opiant Pharmaceuticals, Inc. Exhibit 1 October 4, 2018 Opiant Pharmaceuticals, Inc. Attn: Dr. Roger Crystal, Chief Executive Officer 201 Santa Monica Boulevard, Suite 500 Santa Monica, CA 90401 Re: Beneficial Ownership Limitation Dear Dr. Crystal: Reference is made to the Separation Agreement and General Release (the “Agreement”), dated as of September 5, 2017, between Opiant Pharmaceuticals, Inc. (the “Company”) and myself.
October 9, 2018	SC 13G	OPNT / Opiant Pharmaceuticals, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 683750103 (CUSIP Number) September 26, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
October 9, 2018	SC 13D/A	OPNT / Opiant Pharmaceuticals, Inc. / Pollack Kevin - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) Kevin Pollack c/o Sheppard Mullin Richter & Hampton LLP Attn: Robert L. Wernli, Jr., Esq. 12275 El Camino Real,
September 27, 2018	EX-1.1	Underwriting Agreement, dated as of September 25, 2018, by and between Opiant Pharmaceuticals, Inc. and Cantor Fitzgerald & Co. Exhibit 1.1 OPIANT PHARMACEUTICALS, INC. 705,882 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement September 25, 2018 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Opiant Pharmaceuticals, Inc., a Delaware corporation (the “Company”), prop
September 27, 2018	EX-99.1	Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock Exhibit 99.1 Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock SANTA MONICA, CA, September 25, 2018 – Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug abuse, today announced the pricing of an underwritten public offering of 705,882 shares of its common stock at a public offering pr
September 27, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Co
September 26, 2018	424B5	705,882 Shares OPIANT PHARMACEUTICALS, INC. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-220976 PROSPECTUS SUPPLEMENT (To Prospectus dated November 7, 2017) 705,882 Shares OPIANT PHARMACEUTICALS, INC. Common Stock We are offering 705,882 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “OPNT”. On September 25, 2018, the last reported sale price of our common stock was $17.35 per s
September 25, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Co
September 25, 2018	EX-99.1	Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock Exhibit 99.1 Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock SANTA MONICA, CA, September 24, 2018 - Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an
September 24, 2018	424B5	SUBJECT TO COMPLETION, DATED SEPTEMBER , 2018 Filed Pursuant to Rule 424(b)(5) Registration No. 333-220976 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer
September 20, 2018	EX-10.86	Contract between the Company and Biomedical Advanced Research and Development Authority dated September 19, 2018. EXHIBIT 10.86 * Certain confidential information contained in this document, marked [**], is filed separately with the Securities and Exchange Commission. EXHIBIT 10.86 Certain confidential information contained in this document, marked [***], is filed separately with the Securities and Exchange Commission. EXHIBIT 10.86 CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAV
September 20, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Co
September 14, 2018	SC 13G	OPNT / Opiant Pharmaceuticals, Inc. / Valour Fund, Llc - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 683750103 (CUSIP Number) September 5, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
September 10, 2018	EX-10.84	Development and Manufacturing Agreement between the Registrant and Aesica Queensborough Limited dated September 7, 2018 (incorporated by reference to Exhibit 10.84 of the Company’s Current Report on Form 8-K filed September 10, 2018). Exhibit 10.84 CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DATED: SEPTEMBER 7, 2018 AESICA QUEENBOROUGH LIMITED and OPIANT PHARMACEUTICALS INC DEVELOPMENT AGREEMENT re: development of a device capable of administering Nalmefene hydrochloride Exhibit 10.84 Index Clause No. Page No
September 10, 2018	EX-10.85	Agreement for Reimbursement of Capital Expenditures and Service Fees between the Registrant and Aesica Queensborough Limited dated September 7, 2018 (incorporated by reference to Exhibit 10.85 of the Company’s Current Report on Form 8-K filed September 10, 2018). Exhibit 10.85 CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION EXECUTION COPY AGREEMENT FOR REIMBURSEMENT OF CAPITAL EXPENDITURE AND SERVICE FEES BETWEEN AESICA QUEENBOROUGH LIMITED And OPIANT PHARMACEUTICALS INC relating to the development, manufacture and supply of a device capable
September 10, 2018	EX-99.1	Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose Exhibit 99.1 Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose SANTA MONICA, CA, and HEMEL HEMPSTEAD, UK, September 10, 2018 – Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, and Co
September 10, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
August 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
August 9, 2018	EX-99.1	Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update SANTA MONICA, Calif, August 9, 2018 – Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today reported financial results for the quarter and six months ended June 30, 20
August 9, 2018	10-Q	OPNT / Opiant Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT PH
June 13, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
June 12, 2018	EX-99.1	Stanley Higgins Exhibit 99.1 805 King Farm Blvd. Rockville, MD 20850 / USA business.nasdaq.com Stanley Higgins Senior Director Listing Qualifications The Nasdaq Stock Market LLC +1 301 978 8041 Sent via Electronic Delivery to: [email protected] June 12, 2018 Mr. David D. O’Toole Chief Financial Officer Opiant Pharmaceuticals, Inc. 201 Santa Monica Boulevard, Suite 500 Santa Monica, CA 90401 Re: Opiant Pharmaceut
June 12, 2018	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
June 12, 2018	EX-10.1	Director Agreement, effective June 12, 2018 by and between Opiant Pharmaceuticals, Inc. and Richard Daly. Exhibit 10.1 OPIANT PHARMACEUTICALS, INC. DIRECTOR AGREEMENT This DIRECTOR AGREEMENT (this “Agreement”) by and between Richard Daly (“Director”) and Opiant Pharmaceuticals, Inc. (“Company”), with its corporate headquarters at 201 Santa Monica Blvd., 5th Floor, Santa Monica, CA 90401, is dated and effective as of June 12, 2018 (the “Appointment Date”). W I T N E S S E T H: WHEREAS, Company wishes t
June 12, 2018	EX-99.1	Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors Exhibit 99.1 Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors SANTA MONICA, Calif., June 12, 2018 - Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member o
June 12, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commiss
May 10, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commissio
May 10, 2018	EX-99.1	Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update Exhibit 99.1 Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update SANTA MONICA, Calif, May 08, 2018 - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first quarter ended March 31, 2018, and provided a corporate
May 8, 2018	10-Q	OPNT / Opiant Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-38193 OPIANT P
April 18, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Commis
April 18, 2018	EX-99.1	Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose Grant Expected to Fund Development of OPNT003 to NDA Ready St Exhibit 99.1 Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose Grant Expected to Fund Development of OPNT003 to NDA Ready Stage SANTA MONICA, Calif., April 18, 2018 - Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company dev
April 17, 2018	DEFA14A	OPNT / Opiant Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant þ Filed by a Party other than the ¨ Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
April 17, 2018	DEF 14A	OPNT / Opiant Pharmaceuticals, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive P
April 11, 2018	S-8	OPNT / Opiant Pharmaceuticals, Inc. S-8 As filed with the Securities and Exchange Commission on April 11, 2018 Registration No.
March 19, 2018	424B5	OPIANT PHARMACEUTICALS, INC. Up to $20,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-220976 PROSPECTUS SUPPLEMENT (To the Prospectus Supplement dated November 7, 2017 and the Prospectus dated November 7, 2017) OPIANT PHARMACEUTICALS, INC. Up to $20,000,000 Common Stock This Prospectus Supplement amends and supplements the information in our prospectus, dated November 7, 2017 (File No. 333-220976) (the “Prospectus”), and our Sal
March 7, 2018	10-KT	OPNT / Opiant Pharmaceuticals, Inc. 10-KT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KT ¨ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ý TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from August 1, 2017 to December 31, 2017 Commission file number: 001-38193 OPIANT PHARMACEUTICALS, INC. (Exact
March 5, 2018	EX-10.1	License Agreement, dated as of December 15, 2014, by and between the Company and Adapt Pharma Operations Limited (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 5, 2018). Exhibit 10.1 Confidential Treatment has been granted for portions of this exhibit. The copy filed herewith omits certain information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT between LIGHTLAKE THERAPEUTICS INC. and ADAPT PHARMA OPERATIONS LIM
March 5, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38193 46-4744124 (State or other jurisdiction of incorporation) (Com
February 28, 2018	SC 13D	OPNT / Opiant Pharmaceuticals, Inc. / Pollack Kevin - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 683750103 (CUSIP Number) Kevin Pollack c/o Sheppard Mullin Richter & Hampton LLP Attn: Robert L. Wernli, Jr., Esq. 12275 El Camino Real,
February 28, 2018	SC 13D	OPNT / Opiant Pharmaceuticals, Inc. / Crystal Roger - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 683750103 (CUSIP Number) Dr. Roger Crystal c/o Opiant Pharmaceuticals, Inc. 201 Santa Monica Blvd., 5th Floor Santa Monica, CA 90401 (310
February 28, 2018	SC 13D	OPNT / Opiant Pharmaceuticals, Inc. / Sinclair Michael - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Opiant Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 683750103 (CUSIP Number) Dr. Michael Sinclair c/o Opiant Pharmaceuticals, Inc. 201 Santa Monica Blvd., 5th Floor Santa Monica, CA 90401 (

OPNT / Opiant Pharmaceuticals Inc - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)